share_log

長江生命科技：關於針對 KRAS 及 PD-L1 癌症疫苗臨床前研究的業務進展更新及與晶泰科技進行研究合作的進展

CKLIFE SCIENCES: BUSINESS UPDATE ON PRECLINICAL STUDIES OF CANCER VACCINES TARGETING KRAS AND PD-L1 AND THE PROGRESS OF RESEARCH COLLABORATION WITH XTALPI

香港交易所 ·  Apr 5 00:05
Summary by Moomoo AI
長江生命科技宣佈，將於2024年在美國加州聖地牙哥舉行的美國癌症研究協會年會上，展出針對KRAS及PD-L1癌症疫苗的臨床前研究新數據。KRAS蛋白與多種癌症相關，而PD-L1蛋白則是免疫檢查點蛋白，兩者在癌症治療中扮演重要角色。公司目前的研究顯示，新型合成長肽疫苗在小鼠模型中能誘發抗腫瘤效能。此外，公司與晶泰科技合作，利用人工智能平台設計癌症疫苗，並於同一會議上展示相關數據。公司表示，這些臨床前研究結果令人鼓舞，希望未來能推進至臨床階段。然而，公司強調目前尚未進行臨床試驗，並提醒股東及潛在投資者在交易時需審慎。
長江生命科技宣佈，將於2024年在美國加州聖地牙哥舉行的美國癌症研究協會年會上，展出針對KRAS及PD-L1癌症疫苗的臨床前研究新數據。KRAS蛋白與多種癌症相關，而PD-L1蛋白則是免疫檢查點蛋白，兩者在癌症治療中扮演重要角色。公司目前的研究顯示，新型合成長肽疫苗在小鼠模型中能誘發抗腫瘤效能。此外，公司與晶泰科技合作，利用人工智能平台設計癌症疫苗，並於同一會議上展示相關數據。公司表示，這些臨床前研究結果令人鼓舞，希望未來能推進至臨床階段。然而，公司強調目前尚未進行臨床試驗，並提醒股東及潛在投資者在交易時需審慎。
Changjiang Life Technologies announced that it will present new pre-clinical research data on KRAS and PD-L1 cancer vaccines at the American Association for Cancer Research Annual Meeting in San Diego, California, USA in 2024. KRAS PROTEIN IS ASSOCIATED WITH MANY CANCERS, WHILE PD-L1 IS AN IMMUNE CHECKPOINT PROTEIN, BOTH OF WHICH PLAY AN IMPORTANT ROLE IN CANCER TREATMENT. The company's current study shows that a novel synthetic peptide vaccine induces anti-tumor performance in a mouse model. In addition, the company partnered with Jingtai Technologies to design cancer vaccines using artificial intelligence platforms and present relevant data at the same conference. The company said that these pre-clinical study results are encouraging and hope to advance to the clinical stage in the future. However, the company stressed that clinical trials have not yet been conducted and reminded shareholders and potential investors to exercise caution when trading.
Changjiang Life Technologies announced that it will present new pre-clinical research data on KRAS and PD-L1 cancer vaccines at the American Association for Cancer Research Annual Meeting in San Diego, California, USA in 2024. KRAS PROTEIN IS ASSOCIATED WITH MANY CANCERS, WHILE PD-L1 IS AN IMMUNE CHECKPOINT PROTEIN, BOTH OF WHICH PLAY AN IMPORTANT ROLE IN CANCER TREATMENT. The company's current study shows that a novel synthetic peptide vaccine induces anti-tumor performance in a mouse model. In addition, the company partnered with Jingtai Technologies to design cancer vaccines using artificial intelligence platforms and present relevant data at the same conference. The company said that these pre-clinical study results are encouraging and hope to advance to the clinical stage in the future. However, the company stressed that clinical trials have not yet been conducted and reminded shareholders and potential investors to exercise caution when trading.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more